U
RXII

UBS’s GALENA BIOPHARMA INC COM RXII Stock Holding History

UBS’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$123K Sell
59,991
-36,117
-38% -$74.1K ﹤0.01% 5753
2014
Q2 		$295K Sell
96,108
-17,799
-16% -$54.6K ﹤0.01% 4764
2014
Q1 		$285K Sell
113,907
-388,432
-77% -$972K ﹤0.01% 4814
2013
Q4 		$2.49M Buy
502,339
+115,020
+30% +$570K ﹤0.01% 2583
2013
Q3 		$883K Buy
387,319
+114,567
+42% +$261K ﹤0.01% 3488
2013
Q2 		$605K Buy
+272,752
New +$605K ﹤0.01% 3903

Other funds holding RXII

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS's RXII Position: Q3 2014 in Review

UBS reduced its GALENA BIOPHARMA INC COM (RXII) stake by 38% in Q3 2014, selling an estimated $74.1K and leaving 59,991 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #5753.

UBS first reported a position in RXII in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.49M in Q4 2013. 85 funds tracked by Wall St. Rank hold RXII as of Q3 2014.

  • UBS held 59,991 shares of GALENA BIOPHARMA INC COM worth $123K as of Q3 2014.
  • UBS sold 36,117 GALENA BIOPHARMA INC COM shares in Q3 2014, an estimated $74.1K.
  • GALENA BIOPHARMA INC COM made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5753 holding.
  • UBS first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and has held it in 6 quarters since.
  • UBS's GALENA BIOPHARMA INC COM position peaked at $2.49M in Q4 2013.
  • 85 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.